ArticleScientific reports2026
Subendometrial platelet-rich plasma injection for refractory thin endometrium: a prospective pilot study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To evaluate the effectiveness of subendometrial autologous platelet-rich plasma (PRP) injections in improving endometrial thickness (EMT) and pregnancy outcomes in women with refractory thin endometrium. This prospective, single-arm, self-controlled trial was conducted at Nanjing Drum Tower Hospital between October 2023 and October 2024. A total of 21 women with refractory thin endometrium (EMT < 7 mm), including those with a history of multiple failed treatments (e.g., high-dose oestrogen, surgical adhesiolysis), were treated with subendometrial PRP injections. EMT and reproductive outcomes were assessed before and after PRP treatment. Subendometrial blood flow, intrauterine adhesion (IUA) status, and platelet count (PLT) were also evaluated. Data from pre- and posttreatment cycles were analysed using paired t-tests for continuous variables and Fisher's exact tests for categorical variables. Among the 21 enrolled patients, 18 completed the study. With respect to the baseline characteristics, the mean age of the patients was 36.7 years and the mean duration of infertility was 3.0 years (IQR 2.0-5.25). PRP treatment resulted in a significant increase in EMT from 6.55 mm (IQR 6.08-7.03) to 7.50 mm (IQR 6.78-8.10) (p < 0.001). In 12 patients (66.7%), the EMT reached ≥ 7 mm posttreatment. Despite these improvements, significant enhancement in EMT was not observed in 2 patients with severe adhesions. The clinical pregnancy rate (CPR) in frozen-thawed embryo transfer (FET) cycles was 44.4%, with 8 pregnancies (2 live births, 6 ongoing). A decrease in cancellation rates posttreatment (2.62 vs. 0.71, p = 0.016) was observed. The procedure was safe and well tolerated, with no serious adverse events reported. The PLT in PRP was 3.69 times higher than that in whole blood (p < 0.001), but there was no significant difference in serum oestradiol levels before and after PRP. Subendometrial PRP injections improved EMT and achieved a clinical pregnancy rate of 44.4% in this cohort. This approach may represent a promising alternative for patients with refractory thin endometrium unresponsive to conventional therapies, potentially enhancing fertility outcomes in ART cycles. As a small pilot study, these results are preliminary and should be interpreted with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.